Ingredient · Evidence grade C
Black cohosh for menopause: evidence, studies and safety
Last updated · 14 studies summarized
C Short answer: Black cohosh is the most-studied herb for occasional hot flashes and night sweats associated with menopause*. Independent trials and a Cochrane review found no clear benefit over placebo, other reviews found a small one, and rare liver-injury reports exist.
Key facts
| Evidence grade | C C (iCR extract specifically: C+) |
|---|---|
| Use studied | hot flashes / menopausal symptoms |
| Trials | ≥16 RCTs in Cochrane 2012; 22 articles in Sadahiro 2023 MA |
| Participants | ~2,000–2,300 in RCT meta-analyses (manufacturer review counts 43,759 incl. observational) |
| What reviews conclude | Cochrane 2012 (16 RCTs, 2,027 women): no difference vs placebo for hot-flush frequency. Sadahiro 2023 MA: small-moderate benefit (g 0.32 hot flashes). Manufacturer-affiliated iCR MA (2021): positive, dose-dependent. Large independent US trials (HALT 2006, Geller 2009, Pockaj 2006) null. IMS 2026 review: moderate certainty for benefit. |
| The Menopause Society (2023) | Not recommended (Level I) – 'insufficient evidence to support use for VMS'. |
| Also known as | Remifemin, iCR, Cimicifuga |
Grades: A strong · B moderate · C limited · D none or negative. How we grade.
Every study we reviewed
Each summary gives who took part, the dose, how long, the result compared with placebo or control, and who paid for it.
-
Black cohosh (Cimicifuga spp.) for menopausal symptoms.
An independent Cochrane review pooled 16 trials with about 2,000 women taking black cohosh (usually 40 mg a day for around 5 months). Women taking black cohosh did not have fewer hot flashes than women on a dummy pill, and the reviewers called the safety data inconclusive.
- Who
- 16 RCTs, 2,027 women
- Dose
- median 40 mg/day black cohosh extract
- Duration
- mean 23 weeks
- Result
- No difference vs placebo in hot-flush frequency (MD +0.07/day; 95% CI -0.43 to 0.56; 3 trials, 393 women) or symptom scores; hormone therapy beat black cohosh.
- Funding
- Cochrane review (independent). Independent / academic
-
Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis.
A 2023 analysis of 22 studies (about 2,300 women) found black cohosh extracts did somewhat better than placebo for overall menopause symptoms and hot flashes, with a small-to-moderate effect. It did not help anxiety or low mood, and the studies varied a lot in product and quality.
- Who
- 22 articles, 2,310 women
- Dose
- various black cohosh extracts
- Duration
- various
- Result
- Pooled improvement vs placebo in overall menopausal symptoms (Hedges g 0.58) and hot flashes (g 0.32); no significant effect on anxiety or depression.
- Funding
- Academic; one author reported speaker fees from supplement/pharma companies incl. Cimic. Some author ties
-
Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.
This review looked only at the specific black cohosh extract in Remifemin and found it beat placebo for menopause symptoms, especially at higher doses or combined with St John's wort. Several authors work for the company that makes Remifemin, so read it as a manufacturer-backed summary.
- Who
- 35 studies + 1 MA, 43,759 women (13,096 on iCR)
- Dose
- isopropanolic extract (iCR, Remifemin), 20–>40 mg/day
- Duration
- various
- Result
- SMD -0.69 vs placebo for neurovegetative/psychological symptoms; larger effect at higher dose and with St John's wort; no hepatotoxicity signal in trial data.
- Funding
- Co-authored by staff of Schaper & Brümmer (maker of Remifemin) – manufacturer-affiliated. Industry-linked
-
Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.
About 300 women with menopause symptoms took Remifemin-type black cohosh (40 mg a day) or a dummy pill for 12 weeks. Symptom scores improved more with black cohosh, mostly in women early in menopause, and side effects were similar to placebo.
- Who
- 304 women
- Dose
- iCR (Remifemin) equivalent to 40 mg root/day
- Duration
- 12 weeks
- Result
- More effective than placebo on the Menopause Rating Scale (P<.001), mainly in early menopause; hot-flush subscore was the most responsive.
- Funding
- Funding not stated in the abstract (study of the manufacturer's extract). Funding not stated
-
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
In a publicly funded US trial, 132 women took black cohosh (20 mg twice a day) or placebo for 4 weeks each. Hot flashes dropped slightly more on placebo than on black cohosh, so the trial found no benefit.
- Who
- 132 women (history of or concern about breast cancer; crossover)
- Dose
- black cohosh 20 mg twice daily
- Duration
- two 4-week periods (crossover)
- Result
- Hot-flash frequency fell 17% on black cohosh vs 26% on placebo (P=.36) – no benefit.
- Funding
- NCCTG/NCI cooperative group (public funding). Independent / academic
-
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
The US government-funded HALT study followed 351 women for a year. Black cohosh (160 mg a day), a 10-herb blend, and the blend plus more soy food did no better than a dummy pill for hot flashes, while hormone therapy clearly worked.
- Who
- 351 women aged 45–55
- Dose
- black cohosh 160 mg/day; multibotanical; multibotanical + soy diet; hormone therapy; placebo
- Duration
- 12 months
- Result
- No herbal arm differed from placebo at 3, 6 or 12 months (<1 hot flash/day difference); hormone therapy reduced ~4 symptoms/day vs placebo.
- Funding
- US NIH (NCCAM/NIA) – HALT study, independent. Independent / academic
-
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
In a year-long, government-funded trial, women took black cohosh, red clover, hormone therapy or a dummy pill. Only hormones beat placebo for hot flashes; both herbs looked safe but did not reduce hot flashes more than placebo.
- Who
- 89 women (4 arms)
- Dose
- standardized black cohosh and red clover extracts vs CEE/MPA vs placebo
- Duration
- 12 months
- Result
- Hot-flash reduction: black cohosh 34%, red clover 57%, placebo 63%, hormones 94%; neither botanical beat placebo. Both appeared safe over 12 months.
- Funding
- NIH (NCCAM/ODS) botanical center, University of Illinois – independent. Independent / academic
-
Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.
122 women took a different (ethanol-based) black cohosh extract or placebo for 12 weeks. Overall it did not beat placebo; only women with more severe symptoms seemed to benefit, which is a weaker, after-the-fact finding.
- Who
- 122 women with ≥3 hot flashes/day
- Dose
- dried ethanolic black cohosh extract (non-Remifemin)
- Duration
- 12 weeks
- Result
- No superiority over placebo overall; benefit only in subgroup with moderate–severe symptoms (Kupperman ≥20: -47% vs -21%).
- Funding
- Not stated in abstract. Funding not stated
-
Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract.
This analysis of 5 trials found no change in liver blood tests in women taking the Remifemin extract for up to 6 months. It was written by the manufacturer and covers only short-term use.
- Who
- 5 RCTs, 1,117 women
- Dose
- iCR 40–128 mg/day
- Duration
- 3–6 months
- Result
- No effect on liver enzymes (AST/ALT) vs reference groups.
- Funding
- Written by Schaper & Brümmer (Remifemin maker) staff. Industry-linked
-
United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.
The US Pharmacopeia reviewed 30 reports of liver injury in people using black cohosh. It could not prove black cohosh caused them but recommended a label warning to stop and see a doctor if liver symptoms appear.
- Who
- 30 case reports of liver damage
- Dose
- various products
- Duration
- n/a
- Result
- All 30 liver cases rated 'possible' (none probable/certain); USP recommended a cautionary liver label.
- Funding
- US Pharmacopeia expert committee (independent standard-setter). Independent / academic
-
Black cohosh and breast cancer: a systematic review.
A systematic review of black cohosh and breast cancer found no sign it increases breast-cancer risk, but also no proof it reduces hot flashes in women who have had breast cancer.
- Who
- 26 studies (14 RCTs)
- Dose
- various
- Duration
- various
- Result
- No evidence black cohosh raises breast-cancer risk; no proven hot-flash benefit in breast-cancer patients vs placebo.
- Funding
- Academic (Canadian naturopathic/academic group). Independent / academic
-
Actaea racemosa L. Is More Effective in Combination with Rhodiola rosea L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study.
220 women in Georgia took black cohosh alone, black cohosh plus Rhodiola, or placebo for 12 weeks; the combination worked best. An author is paid by the company that sells the combination.
- Who
- 220 women
- Dose
- black cohosh 6.5 mg; black cohosh 500 mg; Rhodiola+black cohosh (Menopause Relief EP); placebo
- Duration
- 12 weeks
- Result
- Rhodiola+black cohosh beat black cohosh alone and placebo on all symptom scales.
- Funding
- Author has contract with Europharma USA (seller) and heads Phytomed AB. Industry-linked
-
Complementary therapies for management of menopausal symptoms: a systematic review to inform the update of the International Menopause Society recommendations on women's midlife health.
A 2026 International Menopause Society evidence review rated black cohosh's benefit for hot flashes as moderate-certainty and most other supplements as low-certainty.
- Who
- 158 studies
- Dose
- various
- Duration
- n/a
- Result
- Moderate-certainty evidence supports black cohosh for vasomotor/menopausal symptoms and vitamin D for fracture risk; most complementary therapies low/very-low certainty.
- Funding
- International Menopause Society review. Independent / academic
-
Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.
244 Chinese women took Remifemin-type black cohosh or the hormone-like drug tibolone for 12 weeks. Symptom scores fell similarly in both groups, but there was no placebo group, so the size of the true effect is unclear.
- Who
- 244 Chinese women
- Dose
- iCR (Remifemin) equivalent to 40 mg/day vs tibolone 2.5 mg/day (no placebo)
- Duration
- 12 weeks
- Result
- Kupperman Index fell similarly with iCR and tibolone; iCR better tolerated.
- Funding
- Not stated in abstract. Funding not stated
Safety
Rare liver injury reports (USP: 30 cases 'possible' causality; ODS: ≥83 cases worldwide, causality unproven). USP-recommended label: discontinue if liver disorder or symptoms of liver trouble. No evidence of increased breast-cancer risk (Fritz 2014), but safety after breast cancer not established (NCCIH). Possible interaction with statins (NCCIH).
Ranked products that contain it
| Product | Amount per day | Score | $/day |
|---|---|---|---|
| Remifemin Menopause Relief | Black cohosh extract (iCR): 40 mg | 61.8 | $0.50 |
| Estroven Menopause Relief + Weight Management | Black cohosh root extract: 40 mg | 58.4 | $0.63 |
| Nature's Way Black Cohosh Premium Extract | Black cohosh root/rhizome extract, standardized 2.5% triterpene glycosides: 80 mg | 51.5 | $0.42 |
| O Positiv MENO Menopause Gummies | Black cohosh root extract: 40 mg | 50.8 | $1.40 |
| Gaia Herbs Menopause Support Daytime | Organic black cohosh root extract: 600 mg | 40.2 | $1.53 |
FAQ
Does Black cohosh help with menopause symptoms?
Black cohosh is the most-studied herb for occasional hot flashes and night sweats associated with menopause*. Independent trials and a Cochrane review found no clear benefit over placebo, other reviews found a small one, and rare liver-injury reports exist. Our evidence grade is C (iCR extract specifically: C+). Cochrane 2012 (16 RCTs, 2,027 women): no difference vs placebo for hot-flush frequency. Sadahiro 2023 MA: small-moderate benefit (g 0.32 hot flashes). Manufacturer-affiliated iCR MA (2021): positive, dose-dependent. Large independent US trials (HALT 2006, Geller 2009, Pockaj 2006) null. IMS 2026 review: moderate certainty for benefit.
Does The Menopause Society recommend Black cohosh?
Not recommended (Level I) – 'insufficient evidence to support use for VMS'. The 2023 nonhormone statement recommends no dietary supplement for hot flashes; talk to a clinician about hormone therapy and prescription options.
Is Black cohosh safe?
Rare liver injury reports (USP: 30 cases 'possible' causality; ODS: ≥83 cases worldwide, causality unproven). USP-recommended label: discontinue if liver disorder or symptoms of liver trouble. No evidence of increased breast-cancer risk (Fritz 2014), but safety after breast cancer not established (NCCIH). Possible interaction with statins (NCCIH). Supplements are not FDA-approved before sale; ask a clinician or pharmacist, especially if you take medication.
Sources
- https://ods.od.nih.gov/factsheets/BlackCohosh-HealthProfessional/
- https://www.nccih.nih.gov/health/providers/digest/menopausal-symptoms-and-complementary-health-practices-science
- https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
- The Menopause Society 2023 nonhormone position statement (PDF)
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.